Progenics Pharmaceuticals Sets First Quarter 2014 Financial Results Call For May 9

TARRYTOWN, N.Y., May 1, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review first quarter 2014 financial results on Friday, May 9, at 8:30 a.m. ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 40933293. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com , and a replay will be available for two weeks.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics' first-in-class PSMA targeted technology platform includes an antibody drug conjugate therapeutic in a phase 2 clinical trial and a small molecule targeted imaging agent in which a phase 2 trial has just completed. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra , an ultra-orphan radiotherapy candidate also in a phase 2 study under a SPA. Progenics' first commercial product, Relistor ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. For additional information, please visit www.progenics.com .          

(PGNX-F)

Editor's Note:

For more information, please visit www.progenics.com . Please follow us on Linkedin.

For more information about Relistor ®, please visit www.relistor.com .
CONTACT: Kathleen Fredriksen         Corporate Development         (914) 789-2871         kfredriksen@progenics.com

company logo

If you liked this article you might like

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

3 Tiny Explosive Biotech Stocks for 2018

3 Tiny Explosive Biotech Stocks for 2018

4 Small-Caps on My Earnings Watch List

4 Small-Caps on My Earnings Watch List